Used primarily in research and development, this deuterated form of bortezomib serves as an internal standard in mass spectrometry for the quantification of bortezomib in biological samples. It aids in pharmacokinetic studies, helping to understand the drug's absorption, distribution, metabolism, and excretion in the body. Additionally, it is employed in proteasome inhibition studies to investigate its efficacy and mechanism of action in cancer therapy, particularly for multiple myeloma and mantle cell lymphoma. Its deuterium labeling allows for precise tracking and analysis, enhancing the accuracy of experimental results.